ID
32071
Descrição
Study ID: 103992 Clinical Study ID: 103992 Study Title: Evaluate immunogenicity, reactogenicity & safety of 2 doses of GSK Biologicals’ oral live attenuated HRV vaccine (RIX4414 at 106.5 CCID50) when given concomitantly with OPV versus given alone (HRV vaccine dose given 15 days after the OPV dose) in healthy infants in Bangladesh Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00139334 https://clinicaltrials.gov/ct2/show/NCT00139334?term=NCT00139334&rank=1 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Rotavirus Vaccine Trade Name: Rotarix Study Indication: Haemophilus influenzae type b; Neisseria Meningitidis This form is for documentation of demographics, informed consent and randomization/treatment number. To be filled in at Visit 1. Timing: Day 0 Age: 6 weeks +/- 1 week
Link
https://clinicaltrials.gov/ct2/show/NCT00139334?term=NCT00139334&rank=1
Palavras-chave
Versões (2)
- 16/10/2018 16/10/2018 - Sarah Riepenhausen
- 16/10/2018 16/10/2018 - Sarah Riepenhausen
Titular dos direitos
GlaxoSmithKline
Transferido a
16 de outubro de 2018
DOI
Para um pedido faça login.
Licença
Creative Commons BY-NC 3.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
GSK Biologicals' oral HRV vaccine given with OPV in infants NCT00139334
Demographics and Administrative Data
- StudyEvent: ODM
Similar models
Demographics and Administrative Data
- StudyEvent: ODM
C0600091 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,2])